Applicability of histoculture drug response assays in colorectal cancer chemotherapy

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3581-3586

  Yoon, Yong Sik ^a,b   Kim, Chan Wook ^a,b   Roh, Seon Ae ^b   Cho, Dong Hyung ^b,c   Kim, Gyu Pyo ^a   Hong, Yong Sang ^a   Kim, Tae Won ^a,b   Kim, Moon Bo ^b   Kim, Jin Cheon ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

Chemotherapy; Colorectal adenocarcinomas; Histoculture drug response assay (HDRA); Molecular targeted therapy; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; ARTICLE; ASSAY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIVITY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GROWTH INHIBITION; HISTOCULTURE DRUG RESPONSE ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR GROWTH;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 84865677134     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Samson DJ, Seidenfeld J, Ziegler K and Aronson N: Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22: 3618-3630, 2004.
2. Blumenthal RD and Goldenberg DM: Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol Biotechnol 35: 185-197, 2007.
3. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D and Ajani JA: American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 29: 3328-3330, 2011.
4. Abbott A: Cell culture: biology's new dimension. Nature 424: 870-872, 2003.
5. Kim JB, Stein R and O'Hare MJ: Three-dimensional in vitro tissue culture models of breast cancer - a review. Breast Cancer Res Treat 85: 281-291, 2004.
6. Robbins KT, Connors KM, Storniolo AM, Hanchett C and Hoffman RM: Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. Arch Otolaryngol Head Neck Surg 120: 288-292, 1994.
7. Furukawa T, Kubota T and Hoffman RM: Clinical applications of the histoculture drug response assay. Clin Cancer Res 1: 305-311, 1995.
8. Hirano Y, Kageyama S, Ushiyama T, Suzuki K and Fujita K: Clinical usefulness of chemotherapy based on an in vitro chemosensitivity test in urothelial cancer patients. Anticancer Res 21: 4061-4066, 2002.
9. Fujita Y, Hiramatsu M, Kawai M, Nishimura H, Miyamoto A and Tanigawa N: Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer. Oncol Rep 21: 499-505, 2009.
10. Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, Hyodo I, Ogawa T and Furukawa T: Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43: 749-756, 2007.
11. Davies JM and Goldberg RM: Treatment of metastatic colorectal cancer. Semin Oncol 38: 552-560, 2011.
12. Sabharwal A and Kerr D: Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Rev Anticancer Ther 7: 477-487, 2007.
13. Hur H, Kim NK, Kim HG, Min BS, Lee KY, Shin SJ, Cheon JH and Choi SH: Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis. Br J Cancer 106: 53-60, 2011.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
15. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH and Hoffman RM: In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 84: 5029-5033, 1987.
16. Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, Ro SG, Kim SY, Kim YS and Lee JS: Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis 24: 209-218, 2009.
17. Kim JC, Shin ES, Kim CW, Roh SA, Cho DH, Na YS, Kim TW, Kim MB, Hyun YL, Ro S, Kim SY and Kim YS: In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer. Anticancer Res 29: 3027-3034, 2009.
18. Moon YW, Choi SH, Kim YT, Sohn JH, Chang J, Kim SK, Park MS, Chung KY, Lee HJ and Kim JH: Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer 109: 1829-1835, 2007.
19. Han SS, Choi SH, Lee YK, Kim JW, Park NH, Song YS, Lee HP and Kang SB: Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer. Cancer Invest 26: 426-430, 2008.
20. Kim HA, Yom CK, Moon BI, Choe KJ, Sung SH, Han WS, Choi HY, Kim HK, Park HK, Choi SH, Yoon EJ and Oh SY: The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer. Breast 17: 19-26, 2008.
21. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD and Somerfield MR: American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22: 3631-3638, 2004.
22. Blumenthal RD: An overview of chemosensitivity testing. Methods Mol Med 110: 3-18, 2005.
23. Hwu P, Bedikian AY and Grimm EA: Challenges of chemosensitivity testing. Clin Cancer Res 12: 5258-5259, 2006.
24. Maitland ML, DiRienzo A and Ratain MJ: Interpreting disparate responses to cancer therapy: The role of human population genetics. J Clin Oncol 24: 2151-2157, 2006.